David Neustaedter
Angel Investor @ Deerfield Management
Boston, United States
David Neustaedter is a Series B investor at Deerfield Management in Boston focused on Medical and Software. As Vice President of Venture Capital at Medtronic, Dave works closely with Medtronic’s leadership to complete new venture capital investments in areas of strategic interest and socialize key developments at existing portfolio companies. Dave has completed a large number of investments over the years and serves or has served as a Director orObserver on approximately 20 Boards including superDimension, Idev, Medina, and Entellus. Prior to Medtronic, Dave served in similar roles at Covidien and Stryker. While at Covidien, he also led a process to prioritize white space opportunities for the company. Earlier in his career, as a healthcare-focused strategy consultant, Dave supported clients on decisions regarding acquisition opportunities and internal R&D prioritization across the medical device, diagnostic and biopharmaceutical industries. He received his Ph.D. in molecular biology from the University of British Columbia, and an MBA from Yale University, and completed post-doctoral fellowships at the Mount Sinai School of Medicine.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries David Neustaedter invests in
Stages David Neustaedter invests in
Countries David Neustaedter invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (33%)
- Software 1 (33%)
- Wellness 1 (33%)
- Health Care 1 (33%)
- Medical Device 1 (33%)
Stage
- Series B 2 (67%)
- Series C 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Reprieve Cardiovascular is a pioneering medical device company focused on innovative fluid management technologies for congestive heart failure. The company's Reprieve technology is being investigated as an innovative fluid management treatment. Providing clinicians with the ability to precisely control a patient’s fluid volume may both enableimproved cardiac care, as well as, be instrumental in the decongestion of acutely decompensated heart failure patients (ADHF). Reprieve Cardiovascular, Inc. and RenalGuard Solutions, Inc. are subsidiaries of parent company CardioRenal Systems, Inc. | $61M / Series B / Aug 13, 2025 | ||
| R3 Vascular creates bioresorbable scaffold technology with a sirolimus coating for the treatment of peripheral arterial disease. R3 Vascular's polymer and proprietary technologies are used to create scaffolds that balance strength and flexibility for the treatment of peripheral arterial disease. The magnitude BRS device is the thinnest BRSever tested in this clinical setting, with a strut thickness of 98 microns across its entire usable range of diameters. | $87M / Series B / May 09, 2024 | ||
| Presidio Medical is a medtech company that develops a transformational neuromodulation platform. It enables people to receive remedies for disorders affecting neuronal activity. | $72M / Series C / Jun 26, 2023 |
Co-Investors
About Deerfield Management
Deerfield Management focuses on advancing healthcare through investment, research, and philanthropic efforts. The firm manages investment strategies that span across public and private markets, targeting companies involved in biotechnology, pharmaceuticals, diagnostics, healthcare services, and medical technology. In addition to capital deployment,Deerfield supports early-stage innovation through strategic partnerships and dedicated facilities that foster scientific research and drug discovery. The organization also operates a philanthropic foundation that funds education, healthcare access, and initiatives aimed at improving health outcomes.
Deerfield Management Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Mussaad Al-Razouki
Operating Partner
|
|||
Cameron Wheeler
Partner
|
|||
|
David Greenwald
Vice President, Business Development
|
|||
Frank Nestle
Partner and Chief Executive Officer
|
|||
Timothy Leahy
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does David Neustaedter invest in?
David Neustaedter invests primarily in Medical, Software and Wellness startups, most often at Series B and Series C stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact David Neustaedter?
Public channels for David Neustaedter include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did David Neustaedter last invest?
The most recent investment recorded for David Neustaedter closed in May 2024. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
